Recent advances in multiplex molecular testing, such as those used by Randox have facilitated syndromic screening of clinical specimens from a single patient sample. Implementation of molecular multiplexing allows rapid, comprehensive patient assessment, which can inform patient care pathways and, by identifying specific causal agents of infection, allow tailored (or no) medical intervention. Randox will discuss the launch of two new molecular platforms in 2019, which will enable fully automated diagnostics of up to 44 different pathogens from a single patient sample.